The success of Moderna's Phase 3 trial has delivered the first pivotal proof-of-concept that mRNA technology can work in oncology, redirecting market attention toward Chinese biotech firms actively building positions in this space.
According to a Citi Research note from August 20 cited by the trading desk, Moderna's Phase 3 win demonstrates that mRNA vaccines can yield clinically meaningful results in tumor treatment. However, multiple hurdles remain before broader application in cancer care, including validating efficacy across indications beyond melanoma, optimizing neoantigen selection, refining lipid nanoparticle (LNP) delivery, and scaling personalized manufacturing. Citi expressed preference for Chinese mRNA players that combine mature platforms, production infrastructure, and the ability to pair vaccines with their own immuno-oncology drugs.
That assessment carries direct relevance for China's innovative drug sector. Jiangsu Hengrui Pharmaceuticals, CSPC Pharmaceutical Group, Akeso Inc, Everest Medicines, and CanSino Biologics have all staked claims in mRNA cancer vaccines, though they sit at different clinical stages and pursue distinct technological paths.
Moderna's Phase 3 Success: Major Proof-of-Concept, But Challenges Remain
Moderna's Phase 3 win marks the first time a personalized mRNA cancer vaccine has demonstrated therapeutic value in a large-scale clinical trial, a milestone for the technology. Yet the success is currently confined to melanoma, and whether it can be replicated across other tumor types remains the core uncertainty. Precise neoantigen selection, LNP delivery efficiency, and the execution capability for personalized small-batch production are all critical bottlenecks limiting broader clinical adoption.
The development of personalized mRNA cancer vaccines is inherently complex—from tumor sample sequencing and neoantigen identification to mRNA construction, LNP encapsulation, and individualized quality release—each step imposes stringent demands on platform integration and production turnaround speed.
Chinese Contenders: Diverging Platform Maturity and Clinical Progress
Among the Chinese mRNA companies under Citi's coverage, Jiangsu Hengrui Pharmaceuticals and CSPC Pharmaceutical Group are viewed as having the strongest overall capabilities.
Jiangsu Hengrui Pharmaceuticals, through its 47%-owned subsidiary RuiHongDi, is developing personalized neoantigen therapies. Its candidate RGL-270, a personalized neoantigen mRNA vaccine, has advanced to Phase 2—among the most advanced programs in China. In a 16-patient open-label investigator-initiated trial (IIT) for post-resection pancreatic cancer, RGL-270 combined with adebrelimab reported an 18-month recurrence-free survival rate of 100% and a 100% vaccine-specific immune response rate, with a median follow-up of 18 months. The dataset is small and non-controlled, so conclusions require confirmation in larger studies. A separate Phase 2 study evaluating RGL-270 plus adebrelimab as adjuvant therapy for high-risk resected non-small cell lung cancer is also underway.
CSPC Pharmaceutical Group's SYS6026 is a therapeutic mRNA vaccine delivered via LNP, targeting HPV16/18 E6 and E7 antigens for HPV-related high-grade cervical squamous intraepithelial lesions, currently in Phase 2. Unlike RGL-270, SYS6026 is a standardized viral antigen vaccine rather than a patient-specific neoantigen product. Its ongoing trial employs a multicenter, randomized, double-blind, placebo-controlled design, offering a clearer path for efficacy validation.
Earlier-Stage Players: Pipeline Potential, Data Still Maturing
Akeso Inc, Everest Medicines, and CanSino Biologics also have mRNA cancer vaccine programs, but they remain at earlier stages.
Akeso Inc's AK154 is a Phase 1 personalized neoantigen mRNA vaccine for adjuvant treatment after pancreatic cancer resection, evaluating monotherapy and combinations with cadonilimab (a PD-1/CTLA-4 bispecific antibody) or ivonescimab (a PD-1/VEGF bispecific antibody). No human data has been disclosed yet. Citi notes that Akeso Inc's proprietary bispecific antibody portfolio gives it the most differentiated internal combination strategy among Chinese developers, making its pipeline optionality worth watching.
Everest Medicines' EVM16 is a Phase 1 personalized neoantigen mRNA vaccine for advanced solid tumors. First-in-human data from 9 patients showed neoantigen-specific T-cell responses in 8, no dose-limiting toxicities, and all treatment-related adverse events at grade 2 or below. Everest Medicines is also developing EVM14, an off-the-shelf tumor-associated antigen mRNA vaccine, covering both personalized and standardized approaches. CanSino Biologics, leveraging its mRNA process and proprietary LNP delivery capabilities, is developing therapeutic mRNA cancer vaccines, including an early-stage glioblastoma program, though its disclosed oncology pipeline remains preclinical or earlier.
Citi's report also mapped the value chain for personalized mRNA cancer vaccines. Tumor and normal sample sequencing is the starting point, creating upstream demand for sequencing platforms and bioinformatics services from firms like MGI Tech and Novogene. Selected neoantigens are then encoded into optimized mRNA constructs, with LNP delivery systems determining intracellular expression efficiency, immune activation strength, and tolerability.
Unlike conventional high-volume vaccines, personalized products demand rapid small-batch manufacturing and patient-level quality release, making CMC execution and treatment turnaround times critical constraints. Platform value ultimately hinges on clinical immunogenicity, recurrence outcomes, and combination data with checkpoint inhibitors—a logic that favors developers holding both vaccine platforms and complementary tumor immunology assets.